Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Nicole M. Kettner, Smruthi Vijayaraghavan, Merih Güray Durak, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 13, pp. 3996-4013
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Recent advances in therapeutic strategies for triple-negative breast cancer
Yun Li, Huajun Zhang, Yulia Merkher, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 457
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Lei Ding, Jiaqi Cao, Wen-Shan Lin, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 1960-1960
Open Access | Times Cited: 453
Role of STAT3 signaling pathway in breast cancer
Jiahui Ma, Li Qin, Xia Li
Cell Communication and Signaling (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 321
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Mónica Álvarez‐Fernández, Marcos Malumbres
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 514-529
Open Access | Times Cited: 283
DNA Repair Pathways in Cancer Therapy and Resistance
Lanya Li, Yidi Guan, Xisha Chen, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 283
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution
Uddalak Bharadwaj, Moses M. Kasembeli, Prema Robinson, et al.
Pharmacological Reviews (2020) Vol. 72, Iss. 2, pp. 486-526
Open Access | Times Cited: 238
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Hon Yan Kelvin Yip, Antonella Papa
Cells (2021) Vol. 10, Iss. 3, pp. 659-659
Open Access | Times Cited: 205
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis
Rasmus Siersbæk, Valentina Scabia, Sankari Nagarajan, et al.
Cancer Cell (2020) Vol. 38, Iss. 3, pp. 412-423.e9
Open Access | Times Cited: 194
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Alisha Ramos, Samira Sadeghi, Hossein Tabatabaeian
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9451-9451
Open Access | Times Cited: 177
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Dana Jurkovičová, Christiana M. Neophytou, Ana Čipak Gašparović, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14672-14672
Open Access | Times Cited: 78
Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance
Hyemin Lee, Amber D. Horbath, Lavanya Kondiparthi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 39
STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma
Carol Lee, ST Cheung
Cancers (2019) Vol. 11, Iss. 11, pp. 1646-1646
Open Access | Times Cited: 102
The Breast Cancer Stem Cells Traits and Drug Resistance
Qinghui Zheng, Mengdi Zhang, Fangfang Zhou, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 89
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer
James R. Whittle, François Vaillant, Elliot Surgenor, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 15, pp. 4120-4134
Open Access | Times Cited: 84
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
Sunil Pancholi, Ricardo Ribas, Nikiana Simigdala, et al.
Oncogene (2020) Vol. 39, Iss. 25, pp. 4781-4797
Open Access | Times Cited: 78
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4870-4882
Open Access | Times Cited: 74
Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: New insight to proliferation and metastasis
Milad Ashrafizadeh, Mohammad Gholami, Sepideh Mirzaei, et al.
Life Sciences (2021) Vol. 270, pp. 119006-119006
Closed Access | Times Cited: 67
Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
Zijie Cai, Jingru Wang, Yudong Li, et al.
Science China Life Sciences (2022) Vol. 66, Iss. 1, pp. 94-109
Closed Access | Times Cited: 61
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6356-6389
Closed Access | Times Cited: 46
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, et al.
Cancer Research (2023) Vol. 83, Iss. 19, pp. 3264-3283
Open Access | Times Cited: 23
Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies
Xiaqing Xu, Xiaohui Pan, Tingting Wang, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 2, pp. 171-178
Open Access | Times Cited: 51
Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
Bashir Lawal, Yen‐Lin Liu, Ntlotlang Mokgautsi, et al.
Biomedicines (2021) Vol. 9, Iss. 1, pp. 92-92
Open Access | Times Cited: 51
Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 Via the JAK2-STAT3-PDL1
Doudou Jing, Wei Wu, Xuanzuo Chen, et al.
Pharmacological Research (2022) Vol. 182, pp. 106287-106287
Open Access | Times Cited: 37
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Gian Luca Rampioni Vinciguerra, Maura Sonego, Ilenia Segatto, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 30
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER + breast cancer with mitotic aberrations
Isabel Soria‐Bretones, Kelsie L. Thu, Jennifer Silvester, et al.
Science Advances (2022) Vol. 8, Iss. 36
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top